Management of pulmonary disease in patients with cystic fibrosis

New England Journal of Medicine

Volumn 335, Issue 3, 1996, Pages 179-188

  Ramsey, Bonnie W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CEFACLOR; CEFALEXIN; CEFALOTIN; CEFIXIME; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DORNASE ALFA; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; NAFCILLIN; OFLOXACIN; PANCREAS ENZYME; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; TIMENTIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL COLONIZATION; BRONCHIECTASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG MIXTURE; ENZYME REPLACEMENT; GENE THERAPY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ION TRANSPORT; LUNG FUNCTION TEST; LUNG INFECTION; MUCOCILIARY CLEARANCE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM;

4-QUINOLONES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CYSTIC FIBROSIS; GENE THERAPY; HUMANS; LUNG DISEASES; PHYSICAL THERAPY MODALITIES;

EID: 0029934215     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199607183350307     Document Type: Review

References (96)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
2. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9.
3. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol 1993;55:609-30.
4. Schwiebert EM, Egan ME, Hwang TH, et al. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995;81:1063-73.
5. Stutts MI, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50.
6. Quinton PM. Cystic fibrosis: a disease of electrolyte transport. FASEB J 1990;4:2709-17.
7. Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis: review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975;2:241-78.
8. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 3. New York: McGraw-Hill, 1995:3799-876.
9. Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB, Accurso FJ. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991; 119:211-7.
10. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. Vol. 64 of Lung biology in health and disease. New York: Marcel Dekker, 1993:219-76.
11. Davis PB. Evolution of therapy for cystic fibrosis. N Engl J Med 1994; 331:672-3.
12. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr 1992;55: 108-16.
13. Zach MS, Oberwaldner B. Chest physiotherapy - the mechanical approach to antiinfective therapy in cystic fibrosis. Infection 1987;15:381-4.
14. Turpin SV, Knowles MR. Treatment of pulmonary disease in patients with cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. Vol. 64 of Lung biology in health and disease. New York: Marcel Dekker, 1993:277-344.
15. The Cystic Fibrosis Foundation Center Committee, Guidelines Subcommittee. Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centers. Am J Dis Child 1990;144: 1311-2.
16. Desmond KJ, Schwenk WF, Thomas E, Beaudry PH, Coates AL. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. J Pediatr 1983;103:538-42.
17. Arens R, Gozal D, Omlin KJ, et al. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150:1154-7.
18. Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study. Pediatr Pulmonol 1995;19:16-22.
19. Prasad SA. Current concepts in physiotherapy. J R Soc Med 1993;86: Suppl 20:23-9.
20. Pfleger A, Theissl B, Oberwaldner B, Zach MS. Self-administered chest physiotherapy in cystic fibrosis: a comparative study of high-pressure PEP and autogenic drainage. Lung 1992;170:323-30.
21. Mortensen J, Falk M, Groth S, Jensen C. The effects of postural drainage and positive expiratory pressure physiotherapy on tracheobronchial clearance in cystic fibrosis. Chest 1991;100:1350-7.
22. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124:689-93.
23. Mellis CM, Levison H. Bronchial reactivity in cystic fibrosis. Pediatrics 1978;61:446-50.
24. Larsen GL, Barron RJ, Cotton EK, Brooks JG. A comparative study of inhaled atropine sulfate and isoproterenol hydrochloride in cystic fibrosis. Am Rev Respir Dis 1979;119:399-407.
25. Sanchez I, De Koster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 1993;104:842-6.
26. Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol 1990;9:80-5.
27. Zach MS, Oberwaldner B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985;131:537-43.
28. Eggleston PA, Rosenstein BJ, Stackhouse CM, Alexander MF. Airway hyperreactivity in cystic fibrosis: clinical correlates and possible effects on the course of the disease. Chest 1988;94:360-5.
29. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
30. 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103:805-11.
31. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 1991;88:473-92.
32. Larsen GL, Barron RJ, Landay RA, Cotton EK, Gonzalez MA, Brooks JG. Intravenous aminophylline in patients with cystic fibrosis: pharmacokinetics and effect on pulmonary function. Am J Dis Child 1980;134:1143-8.
33. Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S. Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 1983;127: 417-21.
34. Potter JL, Spector S, Matthews LW, Lemm J. Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1969;99:909-16.
35. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990;87:9188-92.
36. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Rcspir Dis 1993;148:145-51.
37. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331:637-42.
38. Ramsey BW, Dorkin HL. Practical applications of Pulmozyme. Pediatr Pulmonol 1994,17:404-8.
39. Redding GJ, Restuccia R, Cotton EK, Brooks JG. Serial changes in pulmonary function in children hospitalized with cystic fibrosis. Am Rev Respir Dis 1982;126:31-6.
40. Orenstein DM, Pattishall EN, Nixon PA, Ross EA, Kaplan RM. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation ín patients with cystic fibrosis. Chest 1990;98:1081-4.
41. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-6.
42. Ramsey BW, Wentz KR, Smith AL, et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-7.
43. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987;13:228-53.
44. Tablan OC, Martone WJ, Doershuk CF, et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes. Chest 1987;91:527-32.
45. Beardsmore CS, Thompson JR, Williams A, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-7.
46. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7.
47. Jensen T, Pedersen SS, Hoiby N, Koch C, Flensborg EW. Use of antibiotics in cystic fibrosis: the Danish approach. Antibiot Chemother 1989; 42:237-46.
48. Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1:235-7.
49. Bosso JA, Black PG, Matsen IM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987;82:180-4.
50. Norrby SR. Side-effects of quinolones: comparison between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991;10:378-83.
51. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-85.
52. Radberg G, Nilsson LE, Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother 1990;34:2142-7.
53. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990;27:162-70.
54. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprorfloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991;19:289-96.
55. Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 1986;79:Suppl 12:44-50.
56. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-5.
57. Brummett RE. Drug-induced ototoxicity. Drugs 1980;19:412-28.
58. Abramowsky CR, Swinehart GL. The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity. Hum Pathol 1982;13:934-9.
59. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-8.
60. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8.
61. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
62. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C, Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8.
63. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338:725-6.
64. Wilson FE. Acute respiratory faillure secondary to polymyxin-B inhalation. Chest 1981;79:237-9.
65. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990;62:1227-33. [Erratum, Cell 1993;73 815.]
66. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for testoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-5.
67. Alton EWFW, Geddes DM. Gene therapy for cystic fibrosis: a clinical perspective. Gene Ther 1995;2:88-95.
68. Korst RJ, McElvaney NG, Chu CS, et al. Gene therapy tor the respiratory manifestations of cystic fibrosis. Am J Respir Crit Care Med 1995; 151:S75-S87.
69. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis Nat Genet 1994;8:42-51.
70. Zabner J, Conture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75:207-16.
71. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-31.
72. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-55.
73. Caplen NJ, Alton-EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46.
74. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-15.
75. + transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclasc activation. J Clin Invest 1986;78:1245-52.
76. Boucher RC. Drug therapy in the 1990s: what can we expect for cystic fibrosis? Drugs 1992;43:431-9.
77. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-94.
78. + ionophores in cystic fibrosis airway epithelia. Am J Physiol 1989; 256:C226-C233.
79. Burnstock G. Overview: purinergic mechanisms. Ann N Y Acad Sci 1990;603:1-18.
80. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533-8.
81. Harper TB, Gaumer HR, Waring W, Brannon RB, Salvaggio JE. Cell mediated immunity and suppressor T cell function in children with cystic fibrosis. Lung 1980;157:219-28.
82. Santos II, Hill HR. Neutrophil function in cystic fibrosis. In: Shapira E, Wilson GB, eds. Immunologic aspects of cystic fibrosis. Boca Raton, Fla.: CRC Press, 1984:29-37.
83. Moss RB, Hsu YP, Lewiston NJ, et al. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and cxotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis 1986;133:648-52.
84. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalvcolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-54. [Erratum, Am J Respir Crit Care Med 1995;151:260.]
85. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JE Jr, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-35.
86. Berger M, Sorensen RU, Tosi MF, Dearborn DG, During G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84:1302-13.
87. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-8.
88. Pantin CF, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986; 41:34-8.
89. Eigen HR, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
90. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991;87:245-6.
91. Shimanuki T, Nakamura RM, Dizerega GS. Modulation of leukotaxis by ibuprofen: a quantitative determination in vivo. Inflammation 1985;9: 285-95.
92. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332: 848-54.
93. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990;141:186-92.
94. Aronoff SC, Quinn FJ Jr, Carpenter LS, Novick WJ Jr. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr 1994;125: 992-7.
95. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-4.
96. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-301.